Clinical characteristics of patients with VITT
| VITT . | Sex . | Site of thrombosis . | Platelet count (×109/L) . | D-dimer (mg/L) . | Fibrinogen (g/L) . | Treatment . |
|---|---|---|---|---|---|---|
| 1 | M | Portal vein, splenic vein, superior mesenteric vein | 70 | 114 | 3.0 | Anticoagulant (bivalirudin, fondaparinux, warfarin) |
| 2 | F | Left central venous sinus | 18 | >20 | 0.6 | Anticoagulant (apixaban, argatroban, dabigatran), IVIg |
| 3 | M | Bilateral PE, DVT | 21 | >20 | 2.1 | Anticoagulant (fondaparinux) |
| 4 | M | Portal vein, superior mesenteric vein | 93 | 56 | 1.9 | Anticoagulant (apixaban, bivalirudin, fondaparinux), IVIg |
| 5 | F | PE, DVT | 8 | >10 | 1.7 | Anticoagulant (apixaban, fondaparinux) |
| 6 | F | Central venous sinus | 138 | >10 | 2.9 | Anticoagulant (bivalirudin, dabigatran), IVIg |
| VITT . | Sex . | Site of thrombosis . | Platelet count (×109/L) . | D-dimer (mg/L) . | Fibrinogen (g/L) . | Treatment . |
|---|---|---|---|---|---|---|
| 1 | M | Portal vein, splenic vein, superior mesenteric vein | 70 | 114 | 3.0 | Anticoagulant (bivalirudin, fondaparinux, warfarin) |
| 2 | F | Left central venous sinus | 18 | >20 | 0.6 | Anticoagulant (apixaban, argatroban, dabigatran), IVIg |
| 3 | M | Bilateral PE, DVT | 21 | >20 | 2.1 | Anticoagulant (fondaparinux) |
| 4 | M | Portal vein, superior mesenteric vein | 93 | 56 | 1.9 | Anticoagulant (apixaban, bivalirudin, fondaparinux), IVIg |
| 5 | F | PE, DVT | 8 | >10 | 1.7 | Anticoagulant (apixaban, fondaparinux) |
| 6 | F | Central venous sinus | 138 | >10 | 2.9 | Anticoagulant (bivalirudin, dabigatran), IVIg |
DVT, deep vein thrombosis; F, female; M, male; PE, pulmonary embolism.